Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Differential effects of knowledge and aging on the encoding and retrieval of everyday activities.

Smith ME, Newberry KM, Bailey HR.

Cognition. 2019 Dec 19;196:104159. doi: 10.1016/j.cognition.2019.104159. [Epub ahead of print]

PMID:
31865171
2.

Does semantic knowledge influence event segmentation and recall of text?

Newberry KM, Bailey HR.

Mem Cognit. 2019 Aug;47(6):1173-1187. doi: 10.3758/s13421-019-00926-4.

PMID:
30915653
3.

Temporal Chunking Makes Life's Events More Memorable.

McGatlin KC, Newberry KM, Bailey HR.

Open Psychol. 2019 Jan;1(1):94-105. doi: 10.1515/psych-2018-0007. Epub 2019 Jan 18.

4.

Correction to Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain.

Luo G, Chen L, Easton A, Newton A, Bourin C, Shields E, Mosure K, Soars MG, Knox RJ, Matchett M, Pieschl RL, Post-Munson DJ, Wang S, Herrington J, Graef J, Newberry K, Sivarao DV, Senapati A, Bristow LJ, Meanwell NA, Thompson LA, Dzierba C.

J Med Chem. 2019 Feb 28;62(4):2213. doi: 10.1021/acs.jmedchem.9b00202. Epub 2019 Feb 8. No abstract available.

PMID:
30734560
5.

Production diseases in smallholder pig systems in rural Lao PDR.

Holt HR, Inthavong P, Blaszak K, Keokamphe C, Phongmany A, Blacksell SD, Durr PA, Graham K, Allen J, Donnelly B, Newberry K, Grace D, Alonso S, Gilbert J, Unger F.

Prev Vet Med. 2019 Jan 1;162:110-116. doi: 10.1016/j.prevetmed.2018.11.012. Epub 2018 Nov 29.

6.

Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain.

Luo G, Chen L, Easton A, Newton A, Bourin C, Shields E, Mosure K, Soars MG, Knox RJ, Matchett M, Pieschl RL, Post-Munson DJ, Wang S, Herrington J, Graef J, Newberry K, Sivarao DV, Senapati A, Bristow LJ, Meanwell NA, Thompson LA, Dzierba C.

J Med Chem. 2019 Jan 24;62(2):831-856. doi: 10.1021/acs.jmedchem.8b01550. Epub 2019 Jan 8. Erratum in: J Med Chem. 2019 Feb 28;62(4):2213.

PMID:
30576602
7.

A call to action on prediabetes.

Dugan J, Cantillep A, Newberry K, Shubrook J.

JAAPA. 2018 Oct;31(10):26-30. doi: 10.1097/01.JAA.0000545064.33107.8f. Review.

PMID:
30204618
8.

Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis.

Veletic I, Manshouri T, Newberry KJ, Garnett J, Verstovsek S, Estrov Z.

Br J Haematol. 2019 Apr;185(2):382-386. doi: 10.1111/bjh.15528. Epub 2018 Aug 3. No abstract available.

PMID:
30074241
9.

A network approach for provisional assay recognition of a Hendra virus antibody ELISA: test validation with low sample numbers from infected horses.

Colling A, Lunt R, Bergfeld J, McNabb L, Halpin K, Juzva S, Newberry K, Morrissy C, Loomes C, Warner S, Diallo I, Kirkland P, Broder CC, Carlile G, Loh MH, Waugh C, Wright L, Watson J, Eagles D, Zuelke K, McCullough S, Daniels P.

J Vet Diagn Invest. 2018 May;30(3):362-369. doi: 10.1177/1040638718760102. Epub 2018 Feb 21.

10.

Therapy-related myelofibrosis does not appear to exist.

Masarova L, Todisco G, Manshouri T, Newberry KJ, Cortes JE, Kantarjian HM, Estrov Z, Verstovsek S.

Blood Adv. 2017 May 26;1(14):863-866. doi: 10.1182/bloodadvances.2017007369. eCollection 2017 Jun 13.

11.

Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Masarova L, Yin CC, Cortes JE, Konopleva M, Borthakur G, Newberry KJ, Kantarjian HM, Bueso-Ramos CE, Verstovsek S.

Exp Hematol Oncol. 2017 Nov 9;6:30. doi: 10.1186/s40164-017-0090-5. eCollection 2017.

12.

A genome-wide interactome of DNA-associated proteins in the human liver.

Ramaker RC, Savic D, Hardigan AA, Newberry K, Cooper GM, Myers RM, Cooper SJ.

Genome Res. 2017 Nov;27(11):1950-1960. doi: 10.1101/gr.222083.117. Epub 2017 Oct 11.

13.

Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder.

Bristow LJ, Gulia J, Weed MR, Srikumar BN, Li YW, Graef JD, Naidu PS, Sanmathi C, Aher J, Bastia T, Paschapur M, Kalidindi N, Kumar KV, Molski T, Pieschl R, Fernandes A, Brown JM, Sivarao DV, Newberry K, Bookbinder M, Polino J, Keavy D, Newton A, Shields E, Simmermacher J, Kempson J, Li J, Zhang H, Mathur A, Kallem RR, Sinha M, Ramarao M, Vikramadithyan RK, Thangathirupathy S, Warrier J, Islam I, Bronson JJ, Olson RE, Macor JE, Albright CF, King D, Thompson LA, Marcin LR, Sinz M.

J Pharmacol Exp Ther. 2017 Dec;363(3):377-393. doi: 10.1124/jpet.117.242784. Epub 2017 Sep 27.

PMID:
28954811
14.

Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.

Newberry KJ, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E, Bose P, Daver N, Cortes J, Kantarjian H, Verstovsek S.

Blood. 2017 Aug 31;130(9):1125-1131. doi: 10.1182/blood-2017-05-783225. Epub 2017 Jul 3.

15.

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.

Masarova L, Bose P, Daver N, Pemmaraju N, Newberry KJ, Manshouri T, Cortes J, Kantarjian HM, Verstovsek S.

Leuk Res. 2017 Aug;59:110-116. doi: 10.1016/j.leukres.2017.06.001. Epub 2017 Jun 2.

16.

Identification of an oxytocinase/vasopressinase-like leucyl-cystinyl aminopeptidase (LNPEP) in teleost fish and evidence for hypothalamic mRNA expression linked to behavioral social status.

Elkins EA, Walti KA, Newberry KE, Lema SC.

Gen Comp Endocrinol. 2017 Sep 1;250:58-69. doi: 10.1016/j.ygcen.2017.06.002. Epub 2017 Jun 6.

PMID:
28596078
17.

Effects of BMS-902483, an α7 nicotinic acetylcholine receptor partial agonist, on cognition and sensory gating in relation to receptor occupancy in rodents.

Pieschl RL, Miller R, Jones KM, Post-Munson DJ, Chen P, Newberry K, Benitex Y, Molski T, Morgan D, McDonald IM, Macor JE, Olson RE, Asaka Y, Digavalli S, Easton A, Herrington J, Westphal RS, Lodge NJ, Zaczek R, Bristow LJ, Li YW.

Eur J Pharmacol. 2017 Jul 15;807:1-11. doi: 10.1016/j.ejphar.2017.04.024. Epub 2017 Apr 22.

PMID:
28438647
18.

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

Boddu P, Falchi L, Hosing C, Newberry K, Bose P, Verstovsek S.

Leuk Res. 2017 Jul;58:14-22. doi: 10.1016/j.leukres.2017.03.008. Epub 2017 Mar 22. Review.

19.

Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.

Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek S.

Lancet Haematol. 2017 Apr;4(4):e165-e175. doi: 10.1016/S2352-3026(17)30030-3. Epub 2017 Mar 11. Erratum in: Lancet Haematol. 2017 Jun;4(6):e257.

20.

Development of New Benzenesulfonamides As Potent and Selective Nav1.7 Inhibitors for the Treatment of Pain.

Wu YJ, Guernon J, Shi J, Ditta J, Robbins KJ, Rajamani R, Easton A, Newton A, Bourin C, Mosure K, Soars MG, Knox RJ, Matchett M, Pieschl RL, Post-Munson DJ, Wang S, Herrington J, Graef J, Newberry K, Bristow LJ, Meanwell NA, Olson R, Thompson LA, Dzierba C.

J Med Chem. 2017 Mar 23;60(6):2513-2525. doi: 10.1021/acs.jmedchem.6b01918. Epub 2017 Mar 10.

PMID:
28234467
21.

Genomic regulation of invasion by STAT3 in triple negative breast cancer.

McDaniel JM, Varley KE, Gertz J, Savic DS, Roberts BS, Bailey SK, Shevde LA, Ramaker RC, Lasseigne BN, Kirby MK, Newberry KM, Partridge EC, Jones AL, Boone B, Levy SE, Oliver PG, Sexton KC, Grizzle WE, Forero A, Buchsbaum DJ, Cooper SJ, Myers RM.

Oncotarget. 2017 Jan 31;8(5):8226-8238. doi: 10.18632/oncotarget.14153.

22.

Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment?

Falchi L, Bose P, Newberry KJ, Verstovsek S.

Br J Haematol. 2017 Feb;176(3):352-364. doi: 10.1111/bjh.14443. Epub 2016 Dec 16. Review.

PMID:
27984634
23.

Reprint of "Assessing the impact of a joint human-porcine intervention package for Taenia solium control: Results of a pilot study from northern Lao PDR".

Okello AL, Thomas L, Inthavong P, Ash A, Khamlome B, Keokamphet C, Newberry K, Gauci CG, Gabriël S, Dorny P, Thompson RA, Lightowlers MW, Allen J.

Acta Trop. 2017 Jan;165:261-267. doi: 10.1016/j.actatropica.2016.11.010. Epub 2016 Nov 23.

24.

An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.

Rozovski U, Verstovsek S, Manshouri T, Dembitz V, Bozinovic K, Newberry K, Zhang Y, Bove JE 4th, Pierce S, Kantarjian H, Estrov Z.

Haematologica. 2017 Jan;102(1):79-84. doi: 10.3324/haematol.2016.149765. Epub 2016 Sep 29.

25.

Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis.

Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos CE, Newberry KJ, Prijic S, Knez L, Bozinovic K, Harris DM, Spaeth EL, Post SM, Multani AS, Rampal RK, Ahn J, Levine RL, Creighton CJ, Kantarjian HM, Estrov Z.

J Exp Med. 2016 Aug 22;213(9):1723-40. doi: 10.1084/jem.20160283. Epub 2016 Aug 1.

26.

Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.

Chihara D, Masarova L, Newberry KJ, Maeng H, Ravandi F, Garcia-Manero G, Ferrajoli A, Cortes J, Kantarjian H, Verstovsek S.

Leuk Res. 2016 Sep;48:1-5. doi: 10.1016/j.leukres.2016.06.007. Epub 2016 Jun 23.

27.

A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia.

Khan M, Yin CC, Yates A, Newberry KJ, Verstovsek S.

J Pediatr Hematol Oncol. 2017 May;39(4):e196-e198. doi: 10.1097/MPH.0000000000000641.

PMID:
27403772
28.

Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis.

Masarova L, Wang W, Newberry KJ, Kantarjian H, Verstovsek S.

Blood. 2016 Aug 11;128(6):877-80. doi: 10.1182/blood-2016-03-705012. Epub 2016 Jun 20. No abstract available.

29.

Development of a spontaneously active dorsal root ganglia assay using multiwell multielectrode arrays.

Newberry K, Wang S, Hoque N, Kiss L, Ahlijanian MK, Herrington J, Graef JD.

J Neurophysiol. 2016 Jun 1;115(6):3217-28. doi: 10.1152/jn.01122.2015. Epub 2016 Apr 6.

30.

Assessing the impact of a joint human-porcine intervention package for Taenia solium control: Results of a pilot study from northern Lao PDR.

Okello AL, Thomas L, Inthavong P, Ash A, Khamlome B, Keokamphet C, Newberry K, Gauci CG, Gabriël S, Dorny P, Thompson RA, Lightowlers MW, Allen J.

Acta Trop. 2016 Jul;159:185-91. doi: 10.1016/j.actatropica.2016.03.012. Epub 2016 Mar 15.

31.
32.

CETCh-seq: CRISPR epitope tagging ChIP-seq of DNA-binding proteins.

Savic D, Partridge EC, Newberry KM, Smith SB, Meadows SK, Roberts BS, Mackiewicz M, Mendenhall EM, Myers RM.

Genome Res. 2015 Oct;25(10):1581-9. doi: 10.1101/gr.193540.115. Epub 2015 Sep 9.

33.

New Therapeutic Approaches in Polycythemia Vera.

Falchi L, Newberry KJ, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S27-33. doi: 10.1016/j.clml.2015.02.013. Review.

34.

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.

Badar T, Kantarjian HM, Ravandi F, Jabbour E, Borthakur G, Cortes JE, Pemmaraju N, Pierce SR, Newberry KJ, Daver N, Verstovsek S.

Leuk Res. 2015 Sep;39(9):950-6. doi: 10.1016/j.leukres.2015.06.001. Epub 2015 Jun 11.

35.

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.

Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek S.

Blood. 2015 Aug 6;126(6):790-7. doi: 10.1182/blood-2015-03-633404. Epub 2015 Jun 29.

36.

Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.

Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S.

Haematologica. 2015 Aug;100(8):1058-63. doi: 10.3324/haematol.2015.126821. Epub 2015 Jun 18.

37.

Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome.

Masarova L, Newberry KJ, Pierce SA, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S.

Leuk Res. 2015 Aug;39(8):822-7. doi: 10.1016/j.leukres.2015.05.002. Epub 2015 May 12.

38.

Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience.

Masarova L, Cherry M, Newberry KJ, Estrov Z, Cortes JE, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2016;57(1):237-9. doi: 10.3109/10428194.2015.1041392. Epub 2015 Sep 25. No abstract available.

39.

Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus.

Graef JD, Newberry K, Newton A, Pieschl R, Shields E, Luan FN, Simmermacher J, Luchetti D, Schaeffer E, Li YW, Kiss L, Bristow LJ.

Brain Res. 2015 Jun 3;1609:31-9. doi: 10.1016/j.brainres.2015.03.019. Epub 2015 Mar 19.

PMID:
25796435
40.

Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis.

Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S.

Leuk Lymphoma. 2015 Jul;56(7):2092-7. doi: 10.3109/10428194.2014.984703. Epub 2015 Feb 17.

41.

A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.

Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, Garcia-Manero G, Ravandi F, Jabbour E, Dellasala S, Pierce S, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):171-6. doi: 10.1016/j.clml.2014.08.003. Epub 2014 Sep 17.

42.

Clinical significance of microcytosis in patients with primary myelofibrosis.

Strati P, Pemmaraju N, Estrov Z, Cardenas-Turanzas M, Pierce S, Newberry KJ, Daver N, Cortes J, Kantarjian H, Verstovsek S.

Leuk Res. 2014 Oct;38(10):1212-6. doi: 10.1016/j.leukres.2014.08.007. Epub 2014 Aug 28.

43.

Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.

Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S.

Leuk Res. 2014 Sep;38(9):1126-9. doi: 10.1016/j.leukres.2014.06.015. Epub 2014 Jul 6.

44.

Fully automated high-throughput chromatin immunoprecipitation for ChIP-seq: identifying ChIP-quality p300 monoclonal antibodies.

Gasper WC, Marinov GK, Pauli-Behn F, Scott MT, Newberry K, DeSalvo G, Ou S, Myers RM, Vielmetter J, Wold BJ.

Sci Rep. 2014 Jun 12;4:5152. doi: 10.1038/srep05152.

45.

Comorbidities predict worse prognosis in patients with primary myelofibrosis.

Newberry KJ, Naqvi K, Nguyen KT, Cardenas-Turanzas M, Florencia Tanaka M, Pierce S, Verstovsek S.

Cancer. 2014 Oct 1;120(19):2996-3002. doi: 10.1002/cncr.28857. Epub 2014 Jun 10.

46.

Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective.

Desai M, Newberry K, Ou Z, Wang M, Zhang L.

Ther Adv Hematol. 2014 Jun;5(3):91-101. doi: 10.1177/2040620714532124. Review.

47.

ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.

Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S.

Leukemia. 2014 Oct;28(10):2090-2. doi: 10.1038/leu.2014.168. Epub 2014 May 23. No abstract available.

48.

Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

Sever M, Newberry KJ, Verstovsek S.

Leuk Lymphoma. 2014 Dec;55(12):2685-90. doi: 10.3109/10428194.2014.893310. Epub 2014 Mar 17. Review.

49.

In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.

Zhang L, Pham LV, Newberry KJ, Ou Z, Liang R, Qian J, Sun L, Blonska M, You Y, Yang J, Lin X, Rollo A, Tamayo AT, Lee J, Ford RJ, Zhao X, Kwak LW, Yi Q, Wang M.

Mol Cancer Ther. 2013 Nov;12(11):2494-504. doi: 10.1158/1535-7163.MCT-13-0156. Epub 2013 Aug 29.

50.

Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.

Desai M, Newberry KJ, Romaguera J, Zhang L, Ou Z, Wang M.

J Hematol Oncol. 2013 Aug 2;6:55. doi: 10.1186/1756-8722-6-55. Review.

Supplemental Content

Loading ...
Support Center